Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Review

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Clinical and Molecular Hepatology 2022;28(1):17-30.
Published online: July 20, 2021

1Department of Internal Medicine, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea

2Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

3Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea

4Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea

Corresponding author : Yuri Cho Center for Liver and Pancreatobiliary Cancer, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea Tel: +82-31-920-1605, Fax: +82-31-920-0149 E-mail: presh_yuri@hanmail.net, yuricho@ncc.re.kr

Editor: Sang Hoon Ahn, Yonsei University College of Medicine, Korea


These authors contributed equally to this work as co-first authors.

• Received: March 26, 2021   • Revised: July 5, 2021   • Accepted: July 18, 2021

Copyright © 2022 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 21,025 Views
  • 702 Download
  • 63 Web of Science
  • 59 Crossref
  • 65 Scopus
prev next

Citations

Citations to this article as recorded by  Crossref logo
  • The Sustainable Goal of Eliminating Hepatitis B, Functional Cure, and the Prospect of NASVAC: A Review
    Mamun Al Mahtab, Julio CA Rubido, Gerardo E Guillén, Eduardo Penton, Osamu Yoshida, Yoichi Hiasa, Sakirul Khan, Md Abdur Rahim, Noor-E-Alam Mohammad, Ahmed L Moben, Rokshana Begum, Musarrat Mahtab, Sheikh MF Akbar
    Euroasian journal of hepato-gastroenterology.2026; 15(2): 178.     CrossRef
  • Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches
    Prashant Tiwari, Istuti Saraswat, Jyoti Gupta
    Current Microbiology.2026;[Epub]     CrossRef
  • Innate immune recognition and evasion strategies of hepatitis B virus: from DNA to RNA and viral proteins
    Zhenghao Chen, Rui Hu, Huajun Ye, Qiuxun Chen, Yuhang Liu, Xinyu Zhang, Yingting Chen, You Wu, Ciliang Jin
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor
    Aoyi Li, Yan Han, Guanglin Xiao, Zhiling Deng, Chaojing Wen, Ke Qiu, Taiyu He, Hong Ren
    Journal of Clinical Medicine.2026; 15(5): 1826.     CrossRef
  • Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers
    Laura Iulia Bozomitu, Ancuta Lupu, Vasile Valeriu Lupu, Nicoleta Gimiga, Dana Teodora Anton Paduraru, Dana Elena Mîndru, Mihaela Mihai, Carmen Anton, Emil Anton, Mihaela Mitrea, Anca Adam-Raileanu, Lorenza Forna
    International Journal of Molecular Sciences.2026; 27(5): 2464.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA)
    Won-Mook Choi, Ji Won Han, Tae Hyung Kim, Miyoung Choi, Moon Haeng Hur, Hyo Young Lee, Han Ah Lee, Byeong Geun Song, Heechul Nam, Jeong-Ju Yoo, Chang Hun Lee, Gi-Ae Kim, Hye Won Lee, Gwang Hyeon Choi, Young Eun Chon, Yun Bin Lee, Dong Hyun Sinn, Bo Hyun K
    Clinical and Molecular Hepatology.2026; 32(3): 1029.     CrossRef
  • Longitudinal Renal Function Changes and Pilot Mitochondrial Epigenetic Analysis in Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogues
    Güliz Uyar Güleç, Sevin Kırdar, Ceylan Ak, Mehtap Kılıç Eren, Hüseyin Örün
    Viral Hepatitis Journal.2026;[Epub]     CrossRef
  • Predictive factors for clinical cure in the treatment of HBeAg(−) chronic hepatitis B or compensated cirrhosis: a prospective observational study
    Yan-Qing Lv, Ru-Hua Guo, Kun-Yu Liu, Jia-Jie Li, Hui-Fan Ji
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Cobalt Chloride–Mimicked Hepatocyte Cell Hypoxia Induces TREX1, Leading to Hepatitis B Virus Restriction
    Rodolphe Suspène, Vincent Caval, Pierre Khalfi, Emmanuelle Pitré, Agnès Marchio, Pascal Pineau, Jean-Pierre Vartanian
    The Journal of Infectious Diseases.2025; 231(6): 1559.     CrossRef
  • The sV184A Variant in HBsAg Specific to HBV Subgenotype C2 Leads to Enhanced Viral Replication and Apoptotic Cell Death Induced by PERK‐eIF2α‐CHOP‐Mediated ER Stress
    Yu‐Min Choi, Dong Hyun Kim, Eun Ju Cho, Ziyun Kim, Junghwa Jang, Hyunsoo Kim, Su Jong Yu, Bum‐Joon Kim
    Journal of Medical Virology.2025;[Epub]     CrossRef
  • Prediction of long-term HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B
    Hae Lim Lee, Soon Kyu Lee, Ji Won Han, Hyun Yang, Heechul Nam, Pil Soo Sung, Hee Yeon Kim, Sung Won Lee, Do Seon Song, Jung Hyun Kwon, Chang Wook Kim, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
    JHEP Reports.2025; 7(7): 101391.     CrossRef
  • Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry
    Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim
    Journal of Liver Cancer.2025; 25(1): 109.     CrossRef
  • Functional Cure for Hepatitis B Virus: Challenges and Achievements
    Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein
    International Journal of Molecular Sciences.2025; 26(8): 3633.     CrossRef
  • Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis
    Shun Li, Lichen Shi, Cheng Huang, Min Li, Tongtong Meng, Hao Wang, Xinyu Zhao, Xiaoqian Xu, Hong You, Jidong Jia, Yuanyuan Kong
    Annals of Hepatology.2025; 30(2): 101921.     CrossRef
  • A review of the progress and challenges of developing dendritic-based vaccines against hepatitis B virus (HBV)
    Ali Ameri, Hossein Gandomkar, Hanan Hassan Ahmed, Radhwan Abdul Kareem, Hayder Naji Sameer, Ahmed Yaseen, Zainab H. Athab, Mohaned Adil, Iman Ghasemzadeh
    Pathology - Research and Practice.2025; 271: 156025.     CrossRef
  • mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models
    María José Limeres, Rocio Gambaro, Malin Svensson, Silvia Fraude-El Ghazi, Leah Pretsch, Daniel Frank, German A. Islan, Ignacio Rivero Berti, Matthias Bros, Ying K. Tam, Hiromi Muramatsu, Norbert Pardi, Stephan Gehring, Maximiliano L. Cacicedo
    Molecular Therapy.2025; 33(9): 4156.     CrossRef
  • Novel Therapeutics for Hepatocellular Carcinoma
    Mohamed I. Elsaid, Ashish Manne
    Clinics in Liver Disease.2025; 29(4): 673.     CrossRef
  • Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D
    Junjie Liu, Tong Yuan, Lin Xue, Huifang Liang
    Virology Journal.2025;[Epub]     CrossRef
  • Advances in the computational development of hepatitis B virus capsid assembly modulators
    Ke Liu, Shaoqing Du, Weiqiao Deng, Zongjin Qu, Xueping Hu
    Drug Discovery Today.2025; 30(10): 104458.     CrossRef
  • Emerging Trends and Future Directions in the Development of Anti-hepatitis B Therapies: A Horizon Scanning Review
    Kaijie Yao, Hao Feng, Ying Chen, Yun Bao, Mengxia Yan, Wen Li, Bin Wu
    Clinical Drug Investigation.2025; 45(10): 681.     CrossRef
  • Magnitude of Hepatitis B virus and associated factors among chronic liver disease patients admitted to the medical ward at Sheikh Hassen Yabare Comprehensive Specialized Hospital, Jigjiga, Ethiopia: a retrospective study
    Ramadan Budul Yusuf, Getnet Addisu, Ahmed Mohammed Ibrahim, Terefe Gebre, Seid Muhumed Abdilaahi, Bilan Ali Ahmed, Abdulahi Hussen Abdinur, Girma Tadesse Wedajo, Mohamed Omar Osman, Tebelay Dilnessa
    PLOS One.2025; 20(12): e0338702.     CrossRef
  • Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies
    Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang
    World Journal of Gastroenterology.2024; 30(10): 1295.     CrossRef
  • Hepatitis B virus genotypes in precision medicine of hepatitis B-related hepatocellular carcinoma: Where we are now
    Caecilia H C Sukowati, Sri Jayanti, Turyadi Turyadi, David H Muljono, Claudio Tiribelli
    World Journal of Gastrointestinal Oncology.2024; 16(4): 1097.     CrossRef
  • N-Hydroxypiridinedione: A Privileged Heterocycle for Targeting the HBV RNase H
    Dimitrios Moianos, Maria Makri, Georgia-Myrto Prifti, Aristeidis Chiotellis, Alexandros Pappas, Molly E. Woodson, Razia Tajwar, John E. Tavis, Grigoris Zoidis
    Molecules.2024; 29(12): 2942.     CrossRef
  • SOD1 inhibition enhances sorafenib efficacy in HBV‐related hepatocellular carcinoma by modulating PI3K/Akt/mTOR pathway and ROS‐mediated cell death
    Jooyoung Lee, Jiye Kim, Ryunjin Lee, Eunkyeong Lee, Hye‐In An, Yong‐Jae Kwon, Hana Jin, Chan‐Gi Pack, Inki Kim, Young‐In Yoon, Gil‐Chun Park, Eun‐Kyoung Jwa, Jae Hyun Kwon, Jung‐Man Namgoong, Gi‐Won Song, Shin Hwang, Eunyoung Tak, Sung‐Gyu Lee
    Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
  • Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain
    Lanlan Liu, Haoyu Wang, Lulu Liu, Fang Cheng, Haji Akber Aisa, Changfei Li, Songdong Meng
    Viruses.2024; 16(7): 1151.     CrossRef
  • Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
    Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim
    Clinical and Molecular Hepatology.2024; 30(3): 539.     CrossRef
  • Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection
    Kenneth Sherman, Susan Rouster, Heidi Meeds, Marion Peters, Jason Blackard, Paul Horn, Timothy Archampong, Awewura Kwara, Mark Anderson, Michael Stec, Gavin Cloherty
    Pathogens and Immunity.2024; 9(2): 43.     CrossRef
  • Functional cure of chronic hepatitis B-hope or hype?
    Gautam Ray
    World Journal of Hepatology.2024; 16(9): 1199.     CrossRef
  • Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment
    Xiaodi Li, Ling Xu, Lianfeng Lu, Xiaosheng Liu, Yang Yang, Yuanni Wu, Ting Zhu, Xiaoxia Li, Yanling Li, Xiaojing Song, Yang Han, Wei Lyu, Wei Cao, Taisheng Li
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
    Cho-Rong Lee, Sung-Gyoo Park
    Clinical and Molecular Hepatology.2024; 30(4): 724.     CrossRef
  • Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”
    Mehrangiz Dezhbord, Kyun-Hwan Kim
    Clinical and Molecular Hepatology.2024; 30(4): 1028.     CrossRef
  • A case report: cccDNA and pgRNA remain positive in liver tissue in a chronic hepatitis B patient with functional cure
    Wenxiong Xu, Qiumin Luo, Yeqiong Zhang, Chan Xie, Liang Peng
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Increased QPCT gene expression by the hepatitis B virus promotes HBV replication
    Conghui Zhang, Qingfeng Ma, Wei Wang, Hui Song, Xue Wang, Fengxia Xu, Chengliang Zhu, Xinghui Liu, Seth Agyei Domfeh
    PLOS ONE.2024; 19(11): e0312773.     CrossRef
  • Antiviral Therapy for Chronic Hepatitis B Infection Improves Outcomes After Total Hip Arthroplasty: A Multicenter Retrospective Study
    Tao Cheng, Guoyong Li, Huiming Ning, Liang Hao
    The Journal of Arthroplasty.2023; 38(2): 300.     CrossRef
  • The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
    Yuri Cho, Bo Hyun Kim, Joong-Won Park
    Clinical and Molecular Hepatology.2023; 29(1): 99.     CrossRef
  • Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
    Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
    Clinical and Molecular Hepatology.2023; 29(1): 191.     CrossRef
  • Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
    Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip
    Clinical and Molecular Hepatology.2023; 29(1): 113.     CrossRef
  • Overview of the development of HBV small molecule inhibitors
    Huihui Yang, Weiwei Yao, Jinfei Yang
    European Journal of Medicinal Chemistry.2023; 249: 115128.     CrossRef
  • The progress of molecules and strategies for the treatment of HBV infection
    Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang
    Frontiers in Cellular and Infection Microbiology.2023;[Epub]     CrossRef
  • Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice
    Daisuke Ito, Hiroyasu Ito, Tatsuya Ando, Yasuhiro Sakai, Takayasu Ideta, Ken J. Ishii, Tetsuya Ishikawa, Masahito Shimizu
    Hepatology Communications.2023;[Epub]     CrossRef
  • The role of different viral biomarkers on the management of chronic hepatitis B
    Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
    Clinical and Molecular Hepatology.2023; 29(2): 263.     CrossRef
  • The latest global burden of liver cancer: A past and present threat
    Joo Hyun Oh, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(2): 355.     CrossRef
  • Interactions of Na+/taurocholate cotransporting polypeptide with host cellular proteins upon hepatitis B and D virus infection: novel potential targets for antiviral therapy
    Dariusz Zakrzewicz, Joachim Geyer
    Biological Chemistry.2023; 404(7): 673.     CrossRef
  • Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
    Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
  • Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
    Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection
    Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Osamu Yoshida, Julio Aguilar, Guillen Nieto Gerardo, Yoichi Hiasa
    Biomedicines.2023; 11(7): 1944.     CrossRef
  • Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies
    Ankita Singh, Jitendra Kumar, Vijay Kumar
    Current Topics in Medicinal Chemistry.2023; 23(18): 1727.     CrossRef
  • Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA
    An-Qi Zhuang, Yan Chen, Shan-Mei Chen, Wen-Cheng Liu, Yao Li, Wen-Jie Zhang, Yi-Hang Wu
    Viruses.2023; 15(12): 2315.     CrossRef
  • Multitasking Na+/Taurocholate Cotransporting Polypeptide (NTCP) as a Drug Target for HBV Infection: From Protein Engineering to Drug Discovery
    Dariusz Zakrzewicz, Joachim Geyer
    Biomedicines.2022; 10(1): 196.     CrossRef
  • Genotypes Variation and Molecular Epidemiology Of The Hbv Chronic Liver Infection In The Local Population Of Pakistan: An Overview Of The Recent Literature
    Bushra Tahreem, Ghadir Ali, Haroon Ahmad, Asim Shahzad, Muhammad Khurram, Nabiha Naeem, Aquib Nazar, Muhammad Haris, Hassan ., Shahrukh .
    Pakistan BioMedical Journal.2022;[Epub]     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Current Status of Drug Therapy for Chronic Hepatitis B
    显明 尹
    Advances in Clinical Medicine.2022; 12(07): 6196.     CrossRef
  • Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B
    Chan‐Young Jung, Hyung Woo Kim, Jung Il Lee, Hyun Woong Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    Liver International.2022; 42(11): 2408.     CrossRef
  • Design, Synthesis and Evaluation of Novel 4‐(4‐Chlorobenzyl)‐6‐methylpyridazin‐3(2H)‐one Derivatives as Hepatitis B Virus Inhibitors
    Oya Unsal Tan, Jan Moncol, David Durantel
    ChemistrySelect.2022;[Epub]     CrossRef
  • Hepatitis B functional cure and immune response
    Jia-Rui Zheng, Zi-Long Wang, Bo Feng
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • Critical Updates on Chronic Hepatitis B Virus Infection in 2021
    Cyriac A Philips, Rizwan Ahamed, Jinsha K Abduljaleel, Sasidharan Rajesh, Philip Augustine
    Cureus.2021;[Epub]     CrossRef

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Clin Mol Hepatol. 2022;28(1):17-30.   Published online July 20, 2021
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Clin Mol Hepatol. 2022;28(1):17-30.   Published online July 20, 2021
Close

Figure

  • 0
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Image
Figure 1. HBV life cycle and novel drug targets. NTCP, sodium taurocholate cotransporting polypeptide; rcDNA, relaxed circular DNA; cccDNA, covalently closed circular DNA; CRISPR, clustered regularly interspaced short palindromic repeats; Cas9, CRISPR-associated protein 9; ER, endoplasmic reticulum; mRNA, messenger RNA; pgRNA, pregenomic RNA; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; HBcAg, hepatitis B core antigen.
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Drug name Sponsor Target Class Clinical stage NCT number
Myrcludex B (bulevirtide) Hepatera Ltd. Virus entry Peptide II (completed) NCT02881008
NCT02888106
CRV431 Hepion Pharmaceuticals, Inc. Virus entry Analogue of cyclosporine A I (recruiting) NCT03596697
GLS4 (morphothiadine) Sunshine Lake Pharma Co., Ltd. Capsid assembly Small molecules II (recruiting) NCT04147208
NVR 3-778 (AL-3778) Novira Therapeutics, Inc. Capsid assembly Small molecules I (completed) NCT02112799
NCT02401737
AB-506 Arbutus Biopharma Corporation Capsid assembly Small molecules I (terminated) -
AB-836 Arbutus Biopharma Corporation Capsid assembly Small molecules I (not yet recruiting) NCT04775797
JNJ-440 (JNJ-64530440) Alios Biopharma Inc Capsid assembly Small molecules I (completed) NCT03439488
JNJ-56136379 (JNJ-379) Janssen Research & Development, LLC Capsid assembly Small molecules II (completed) NCT03361956
II (recruiting) NCT04667104
ABI-H0731 (vebicovir) Assembly Bioscience Capsid assembly Small molecules II (completed) NCT03577171
II (recruiting) NCT04781647
ABI-H2158 Assembly Bioscience Capsid assembly Small molecules II (recruiting) NCT04398134
EDP-514 Enanta, Pharmaceuticals Capsid assembly Small molecules I (recruiting) NCT04008004
QL-007 Qilu Pharmaceutical Co., Ltd. Capsid assembly Small molecules II (recruiting) NCT04157699
ZM-H1505R Shanghai Zhimeng Biopharma, Inc. Capsid assembly Small molecules I (completed) NCT04220801
RO7049389 (RG7907) Hoffmann-La Roche Capsid assembly Small molecules II (recruiting) NCT04225715
SRI-32007 (CYT997) - Capsid assembly Small molecules Preclinical -
Ciclopirox - Capsid assembly Small molecules Preclinical -
Besifovir IlDong Pharmaceutical Co Ltd Polymerase Small molecules III (active, not recruiting) NCT01937806
IV (recruiting) NCT04202536
Metacavir Guangzhou Yipinhong Pharmaceutical CO., LTD Polymerase Small molecules II (unknown) NCT02965859
HS-10234 Jiangsu Hansoh Pharmaceutical Co., Ltd. Polymerase Small molecules III (recruiting) NCT03903796
Pradefovir Xi’an Xintong Pharmaceutical Research Co.,Ltd. Polymerase Small molecules III (recruiting) NCT04543565
ATI-2173 Antios Therapeutics, Inc Polymerase Small molecules I (recruiting) NCT04248426
GS-5801 Gilead Sciences cccDNA Small molecules I (unknown) -
REP 2139 and REP 2165 Replicor Inc. HBsAg Nucleic acid polymer II (completed) NCT02565719
ALG-010133 Aligos Therapeutics HBsAg Nucleic acid polymer I (recruiting) NCT04485663
ARC-520 Arrowhead Pharmaceuticals Viral transcript Small interfering RNA II (terminated) NCT02577029
JNJ-3989 (ARO-HBV) Arrowhead Pharmaceuticals Viral transcript Small interfering RNA II (completed) NCT03365947
RG6346 Hoffmann-La Roche Viral transcript Small interfering RNA II (recruiting) NCT04225715
AB-729 Assembly Biosciences Viral transcript Small interfering RNA II (recruiting) NCT04820686
VIR-2218 (BRII-835) Vir Biotechology Viral transcript Small interfering RNA II (active, not recruiting) NCT04507269
GSK3389404(GSK404) GlaxoSmithKline Viral transcript Antisense oligonucleotides II (completed) NCT03020745
GSK3228836 (GSK836) GlaxoSmithKline Viral transcript Antisense oligonucleotides II (active, not recruiting) NCT04449029
II (recruiting) NCT04676724
Drug name Sponsor Target Class Clinical stage NCT number
GS-9620 (vesatolimod) Gilead Sciences Toll-like receptor 7 agonists Small molecules II (completed) NCT02166047
GS-9699 (selgantolimod) Gilead Sciences Toll-like receptor 8 agonists Small molecules II (completed) NCT03615066
RG7854 (RG7020531) Hoffmann-La Roche Toll-like receptor 7 agonists Small molecules I NCT04225715
SBT 8320 Silverback Therapeutics Toll-like receptor 8 agonists Small molecules Preclinical -
Nivolumab PharmaEssentia Programmed cell death-1 receptor antagonists Monoclonal antibody I (not yet recruiting) NCT04638439
INO-1800 Inovio Pharmaceuticals Therapeutic vaccines DNA vaccines I (completed) NCT02431312
HB-110 Genexine, Inc. Therapeutic vaccines DNA vaccines I (completed) NCT01641536
GS-4774 Gilead Sciences Therapeutic vaccines T-cell vaccines II (completed) NCT02174276
TG-1050 (T101) Transgene Therapeutic vaccines Adenovirus 5-based vaccines I (completed) NCT02428400
HepTcell Altimmune Therapeutic vaccines Synthetic peptides II (recruiting) NCT04684914
AIC 649 AiCuris Therapeutic vaccines A proprietary inactivated parapoxvirus particle I (completed) -
VBI-2601 (BRII-179) Brill Biosciences Therapeutic vaccines Recombinant protein vaccine I/IIb (completed) -
VTP-300 Vaccitech Therapeutic vaccines Heterologous combination of ChAdOx1 and MVA vectors I/II (recruiting) NCT04778904
JNJ 64300535 Janssen Sciences Therapeutic vaccines Ireland UC DNA vaccines I (completed) NCT03463369
Table 1. Selected novel agents in development for the treatment of chronic hepatitis B

NCT, national clinical trial; cccDNA, covalently closed circular DNA; HBsAg, hepatitis B surface antigen.

Table 2. Selected novel immune modulators in development for the treatment of chronic hepatitis B

NCT, national clinical trial; MVA, modified vaccinia virus Ankara.